by Elka Worner When two Lundquist Institute doctors began their research into HIV and sickle cell disease, getting an HIV diagnosis was a death sentence and…
Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported that on August 18, 2023 the Board of Directors, including Yutaka Niihara, M.D., Ph.D, determined that Dr. Niihara would no longer serve as Chief Executive Officer of Emmaus, or as Chairman of the Board, in order to allow Dr. Niihara to pursue business opportunities in Ube, Japan and in India previously initiated by Emmaus. Dr. Niihara was the p
Emmaus Life Sciences Inc (OTCQX:EMMA) said Dr. Yutaka Niihara will no longer serve as the company’s CEO as Dr. Niihara pursues business opportunities in.
Emmaus Life Sciences Reports Q2 2023 Financial Results Record Net Revenues Contributed to Income from Operations Sixth Straight Quarterly Increase in Net. -Today at 03:28 pm- MarketScreener
/PRNewswire/ Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,.